Losartan Potassium
Product Images NDC 71335-0972

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71335-0972). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl713350972)

Label (Lbl713350972)
This appears to be a product label for Losartan, a medication used to treat high blood pressure. It contains information on the dosage, storage instructions, and manufacturer details. The label also provides a warning to keep this medication out of reach of children. Additionally, it lists the NDC code and expiration date.*
FDA Label Image

Figure 1 (Losartan Fig1)

Figure 1 (Losartan Fig1)
The text appears to be a chart comparing the effectiveness of two drugs, Atenolol and Losartan Potassium, in reducing the risk of the primary endpoint in patients. The chart shows a 13% adjusted risk reduction for Losartan Potassium compared to Atenolol, with a p-value of 0.021. The rows of numbers at the bottom of the chart indicate the study month.*
FDA Label Image

Figure 2 (Losartan Fig2)

Figure 2 (Losartan Fig2)
FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 (Losartan Fig3)
This appears to be a table or chart related to the "Primary Endpoint Events" within demographic subgroups. It shows the results for different groups based on age, gender, race, and other factors. However, due to the poor quality of the text, it is difficult to interpret the data accurately.*
FDA Label Image

Figure-4 (Losartan Fig4)

Figure-4 (Losartan Fig4)
The given text shows the results of a clinical trial for a drug called Losttan Potassium compared to a placebo. The top row shows the percentage of patients who experienced a certain event (not specified in the text), with 60% in the Lostan Potassium group and 40% in the placebo group. The next row shows a risk reduction percentage of 16.1% with a statistically significant p-value of 0.022. Therefore, Lostan Potassium was found to be more effective than the placebo in preventing or reducing the occurrence of the specified event.*
FDA Label Image

Chemical Structure (Losartan Str)

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.